Tile overview image

Curriculum

2.00 CME Credit

The Future of Alzheimer Disease: Early Recognition and Emerging Therapy

This comprehensive curriculum will equip you with the knowledge you need to earlier recognize, accurately diagnose, and appropriately treat patients with Alzheimer disease (AD). Across an array of formats, you will hear experts discuss strategies to mitigate the devastating effects of this progressive disease on patients and those who care for them. Finally, this education will leave you feeling optimistic about the exciting changes on the horizon for AD, including the emergence of potentially disease-modifying treatments, offering hope to clinicians and patients alike.  

Begin

CME Information

2.00 AMA PRA Category 1 Credits™, 2.00 ABIM MOC or 2.10 AANP, including 0.98 AANP Pharm

Release Date: 5/23/2022

Available for credit until 9/20/2023

Learning Objectives

  • Discuss strategies to promote the early detection of mild cognitive impairment (MCI) or dementia in appropriate patients
  • Review the diagnosis of Alzheimer Disease
  • Explore the mechanism of action and evidence supporting new and emerging disease-modifying therapies for Alzheimer disease (AD)
  • Consider which patients are most likely to benefit from these new and emerging disease-modifying therapies
  • Examine the diagnosis of Alzheimer disease (AD) and MCI due to AD, including the emerging role of biomarkers
  • Explore the evidence supporting new and emerging disease-modifying therapies for AD and consider which patients are most likely to benefit from these therapies
 

Courses

Podcast

Clinician talking to elderly person

Why Is Early Detection of Alzheimer Disease So Important?

0.25 CME/MOC

0.30 AANP

Begin

Podcast

Tile overview image

New and Emerging Therapies for Alzheimer Disease: Anti-Amyloid Therapies

0.25 CME/MOC

0.23 AANP | 0.23 Pharmacology

Begin

Webcast

Doctor talking to elderly patient with a caregiver present

Early Detection and Diagnosis of Alzheimer Disease

0.50 CME/MOC

0.53 AANP

Begin

Webcast

modern abstract brain image

New and Emerging Therapies for Alzheimer Disease

0.50 CME/MOC

0.50 AANP | 0.50 Pharmacology

Begin

Podcast

Elderly man with physician

Addressing Clinicians’ Challenges and Misinformation Around Diagnosis of Alzheimer Disease

0.25 CME/MOC

0.29 AANP

Begin

Podcast

Elderly patient holding doctors hands

Addressing Clinicians’ Challenges and Misinformation Around New and Emerging Treatments for Alzheimer Disease

0.25 CME/MOC

0.25 AANP | 0.25 Pharmacology

Begin

Faculty

Daniel Press, MD

Chief, Division of Cognitive Neurology
Associate Professor of Neurology,
Harvard Medical School
Boston, MA

Learn More
Default Biography Avatar

Marwan N. Sabbagh, MD, FAAN

Professor of Neurology, Alzheimer's and Memory Disorders Division
Barrow Neurological Institute
Research Professor, University of Arizona College of Medicine-Phoenix
Clinical Professor of Neurology, Creighton University

Learn More

Gad A. Marshall, MD

Associate Professor of Neurology
Harvard Medical School
Associate Medical Director of Clinical Trials
Center for Alzheimer Research and Treatment
Brigham and Women's Hospital
Assistant in Neurology
Massachusetts General Hospital
Boston, MA

Learn More

CME Information

AMA PRA Category 1 Credits

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and American Kidney Fund. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this endured activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and American Kidney Fund. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

This activity is approved for 1.56 contact hour of continuing education, which includes 0.73 hour of pharmacology.

Supporters and Partners

Commercial Supporter

This activity is supported by an educational grant from Lilly

Education Partner

Pri-Med Institute

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation. Pri-Med Institute and Vindico Medical Education staff have no relevant financial relationships to disclose.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs. 

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The Future of Alzheimer Disease: Early Recognition and Emerging Therapy

Begin